Region — US. Neutral scientific reference — not offered for sale here.
Research reference — not for sale
Peptide
also called — Selank · TP-7 (Tuftsin-Proline-Glycine-Proline) · a tuftsin analog · sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) (MW ~752 Da). INCI: none
anxiolytic (approved: GAD)neuro / cognitive (secondary)immunomodulatory (research context)
Reference entry — not sold here. Like Semax (#41), Selank is an approved prescription drug in Russia — the anxiety-focused sibling to Semax's cognition focus. Credit its real standing; flag that its evidence is Russian and not independently replicated. No dosing published here.
In brief
Selank is a synthetic analog of the immune peptide tuftsin, developed in Russia (same institute and lead investigator as Semax) and approved there as a prescription anxiolytic for generalized anxiety disorder. Its defining feature is anxiety relief without sedation, tolerance, or dependence — a profile no Western-approved anxiolytic achieves cleanly. But its evidence is predominantly Russian and not independently replicated to Western standards, and it is not FDA/EMA approved. It is the anxiety-focused counterpart to Semax (#41), the cognition-focused one.
Legal standing, by region
European Union
Not approved
Not approved; not eligible for magistral/officinal compounding.
United States · your region
Not FDA-approved (gray-market)
Not FDA-approved. Gray-market / research-chemical use; its compounding status falls within the ongoing 2023–2026 FDA peptide review — confirm current status.
International
Approval limited to Russia/CIS
Approval limited to Russia/CIS.
Evidence, by outcome
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
OutcomeEvidence base · effectGrade
Generalized anxiety disorder (on-label in Russia)
Strongest use, but Russian-only, no Western replication; methodology varies from FDA/EMA standards
Russian RCTs — anxiolytic efficacy compared to benzodiazepines (e.g. medazepam), without sedation · Meaningful anxiety reduction
CAnxiolytic mechanism (GABA / enkephalin / BDNF)
Animal/mechanistic; human translation is Russian-only
Preclinical (rodent) + Russian mechanistic work · Multi-target, well-characterised
BCognitive / nootropic (secondary)
Weaker than the anxiety use; often a downstream effect of reduced anxiety
Extrapolated + limited data · Secondary to anxiolysis
DImmune / antiviral (tuftsin heritage)
Preclinical; from its tuftsin origin
Preclinical (cytokine regulation; antiviral fragments) · Suggestive
CGeneral "stress / focus" (biohacker use)
Not the approved use
Extrapolated · Suggestive
DSafety
No sedation, tolerance, or dependence — a genuine advantage over benzodiazepines; long-term / Western data limited
Approved drug (Russia), broad clinical use · Notably clean
—Identity a synthetic heptapeptide (7 amino acids, < 40 aa → peptide) — the endogenous immune peptide tuftsin (Thr-Lys-Pro-Arg) extended with a C-terminal Pro-Gly-Pro tail for metabolic stability. (Note the same Pro-Gly-Pro stabilisation trick used in Semax — a signature of this Russian peptide programme.) ## Development & history - Engineered in the 1990s at the Institute of Molecular Genetics, Russian Academy of Sciences — the same institute as Semax, with Nikolai F. Myasoedov as a principal investigator for both. The design took the immune tetrapeptide tuftsin and stabilised it into the heptapeptide Selank.
- Approved in Russia as a prescription anxiolytic (and nootropic) for generalized anxiety disorder (GAD) and neurasthenia, given intranasally. Its "an immune peptide became an anxiolytic" origin is genuinely part of its identity — the tuftsin heritage is why it also carries immunomodulatory/antiviral activity. ## Mechanism (as proposed) Selank does not act through a single receptor. It is proposed to allosterically modulate GABA-A receptors without binding the benzodiazepine site (hence anxiolysis without the sedation/dependence of benzodiazepines), inhibit enkephalinase (prolonging endogenous enkephalins — the same enzyme family Semax engages), modulate serotonin metabolism, upregulate hippocampal BDNF, and regulate inflammatory cytokines (its tuftsin-derived immune arm). This multi-target profile is offered as the explanation for anxiety relief without single-target trade-offs.
Sources — 4 cited
01(Institute of Molecular Genetics, RAS — Selank development; Myasoedov and colleagues; Russian regulatory registration.)
02(Russian clinical trials of Selank in generalized anxiety disorder / neurasthenia — efficacy vs benzodiazepines; cite specific trials before publishing.)
03Agniullin YaV, Myasoedov NF, et al. (Selank effects on the hippocampal transcription profile — mechanism.)
04Tuftsin / immunomodulation literature (for the antiviral/cytokine arm).
Review status
Not yet reviewed
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026.
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
VallydiaA neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
Region — United States
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.